Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Korea FDA Issues Approval To Chong Kun Dang For Future Sales Of Generic Tamiflu

This article was originally published in PharmAsia News

Executive Summary

SEOUL - The Korea Food & Drug Administration granted approval to local South Korean Chong Kun Dang Pharmaceutical to sell its generic version of Roche's Tamiflu (oseltamivir) at some point in the future

You may also be interested in...

Roche Is Latest MNC To Partner A Primary Care Product In Korea

Handok, which is partially owned by Sanofi, will sell Roche’s Madopar for Parkinson’s disease in Korea.

Korea's Green Cross Gets Green Light From KFDA To Produce Novartis Adjuvanted A/H1N1 Vaccine

SEOUL - South Korean vaccine maker Green Cross said it has received the green light from Korea FDA to use Novartis's MF59 adjuvanted A/H1N1 vaccine for production of an A/H1N1 vaccine

South Korea Plans To Provide Tamiflu and Relenza To North Korea

SEOUL - With information on the spread of the A/H1N1 pandemic in North Korea closely guarded, the South Korean government is moving to supply the antiviral drugs Tamiflu and Relenza to workers in the North's Gaesung Industrial Zone as a gesture of compassion and reconciliation between the two Koreas

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts